Skip to main content

ORIGINAL RESEARCH article

Front. Surg.
Sec. Thoracic Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1506854
This article is part of the Research Topic Clinical and Surgical Perspectives in Sublobar Resection for Lung Cancer View all 4 articles

Postoperative Radiotherapy Improves Survival in Completely Resected Non-Small Cell Lung Cancer with Pathologic N2 Stage IIIA and Positive Lymph Node Count Greater than One: A SEER-Based Retrospective Cohort Study

Provisionally accepted
Yuanyuan Xiao Yuanyuan Xiao Shancheng He Shancheng He Baochang Xie Baochang Xie Wenqi Zhao Wenqi Zhao Dengliang Ji Dengliang Ji *
  • Ganzhou Fifth People's Hospital, Ganzhou, China

The final, formatted version of the article will be published soon.

    Objective: Non-small cell lung cancer (NSCLC) constitutes approximately 85% of lung cancer cases, with 20-30% of patients diagnosed at stage III. While multimodal therapy is the standard for treating locally advanced NSCLC, the role of PORT remains controversial. This study seeks to evaluate the effect of postoperative radiotherapy (PORT) on overall survival (OS) and cancer-specific survival (CSS) in patients with resected pathologic N2 (pN2) stage IIIA NSCLC.: Data from the Surveillance, Epidemiology, and End Results Program (SEER) 17 registry (2010-2019) were analyzed. The cohort included 1,471 patients aged 65 years or older, diagnosed with stage IIIA pN2 NSCLC, who had undergone lobectomy or total pneumonectomy. Patients who had received neoadjuvant chemotherapy or radiotherapy were excluded. Univariate and multivariate analyses were conducted to assess the association of PORT with OS and CSS. Kaplan-Meier survival curves were employed to estimate survival outcomes, while the COX proportional hazards model was utilized for comparative analysis. PLN counts were stratified into two categories: ≤1 and >1.Results: Among the 1,471 patients included in the study, 613 (41.67%) received PORT, while 858 (58.33%) did not.PORT was associated with a significantly higher 1-year and 3-year OS (89.96%

    Keywords: Non-small cell lung cancer, Postoperative radiotherapy, overall survival, positive lymph nodes, Stage IIIA Pathologic N2

    Received: 06 Oct 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Xiao, He, Xie, Zhao and Ji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dengliang Ji, Ganzhou Fifth People's Hospital, Ganzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.